Resources Bio-Outsourcing 
Pharmaceutical Technology
NOVEMBER 21, 2022
The clinical hold placed by Instil Bio on DELTA-1 means that Instil Bio will have to re-evaluate its manufacturing process and will lose precious clinical development time on its way to a biologics license application (BLA).
European Pharmaceutical Review
DECEMBER 26, 2023
Having proprietary cell lines in house can also speed up USP by reducing the need to outsource and the time required to grow the cells before use. Achieving cost optimisation requires identifying opportunities for process simplification, improving productivity and optimising resources.
PharmaShots
APRIL 13, 2023
The idea was coined by the ISPE to integrate discrete aspects like resources, organization & processes, culture, and information systems. Some of the significant transformations carried out to bolster biopharma industries are: Adapting to Pharma 4.0 Model: Inspired by the industry 4.0 model, the pharma 4.0
Expert insights. Personalized for you.
59 
Let's personalize your content